Loading clinical trials...

A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot | Clinical Trials | Clareo Health

RECRUITING

A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot

A Prospective, Post-Market Study to Evaluate the Clinical Utility of the Force Feedback Instruments in RAS Procedures Using the da Vinci 5 Surgical System

NCT06879912•Intuitive Surgical

View on ClinicalTrials.gov

Summary

The goal of this observational study is to understand the utility of force feedback instruments in surgeries that are done using the da Vinci 5 robot.

Eligibility

Age

22 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 22 years or older
•2. ASA ≤ 3
•3. The clinical decision has been made to perform multi-port robotic assisted surgery with da Vinci 5 with Force Feedback instruments for the study specified procedure as primary procedure prior to enrollment in the study
•4. Subject or a legally authorized representative is able to provide written informed consent using the study informed consent form prior to the study
•5. Subject is willing and able to comply with the study protocol requirements including follow up schedule

Exclusion Criteria

•Subject receiving an emergent procedure
•Subject planned to undergo major concomitant surgery for the treatment of a different medical condition than was originally planned
•Subject with previous ipsilateral surgery (open, endoscopic or robotic) with the same surgical indication
•Subject with past or ongoing medical conditions (for example: inflammatory bowel disease) which, in the judgment of the Investigator, puts them at high risk for surgery and not appropriate for the study
•Subject is pregnant or suspected to be pregnant or breastfeeding
•Subject has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete quality data
•Subject is currently participating in or has participated in a study of an investigational agent or a significant risk investigational device study within the past 6 months
•Subject belongs to a vulnerable population.
•Subject is contraindicated for anesthesia or surgery.
•Subject has had previous neoadjuvant therapy, previous chemotherapy, immunotherapy, and/or radiation therapy for the treatment of the cancer to be resected within the past 6 months
+3 more criteria

Locations (5)

University of Miami

Miami, Florida, United States

Northeast Georgia Medical Center, Inc

Gainesville, Georgia, United States

Northwestern Memorial Healthcare

Chicago, Illinois, United States

Ohio State University

Columbus, Ohio, United States

St. David's Healthcare

Austin, Texas, United States

Key Dates

Start Date

May 22, 2025

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2026

Last Updated

February 25, 2026

Enrollment

200

ESTIMATED participants

Conditions

Hernia, InguinalHernia, VentralColorectalThoracicGynecologicPartial Nephrectomy

Contacts

Smruthi Srinivasa Murthy

CONTACT

682-552-6131 smruthi.srinivasamurthy@intusurg.com

Manish Bharara

CONTACT

manish.bharara@intusurg.com

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors